Next-generation pneumococcal conjugate vaccine development for LMICs

Inventprise is developing efficacious, affordable vaccines for global populations most in need. The foundation’s support is helping Inventprise advance the novel pneumococcal conjugate vaccine (IVT-25), which will be made available, accessible, and affordable to low- and middle-income countries. Inventprise will also make its platform available for future vaccine development.
  • Domain
  • Investment type
    Direct equity
  • Status
  • Initial investment
  • Partnered in
  • Investment lead
    Richard Holmes
  • Headquarters
  • Program strategy

More about our work

Our focus

Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.

Investment approach

Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.

Our team

We bring depth of experience to every investment, with a proven track record across sectors and scale.